Exploration of novel treatment of ARONJ with anti-G-CSF antibody using inflammation-induced osteonecrosis of the jaw

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K17126
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: Hyogo Medical University
• Principal Investigator: Ueta Miho 兵庫医科大学, 医学部, 助教 (10774391)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 抗G-CSF中和抗体 / 骨髄炎

Outline of Final Research Achievements

We created a model in which mice were injected with zoledronic acid, silk ligature was tied around the maxillary first molar, and LPS was administered to the surrounding periodontal tissues to induce inflammation. Subsequently, anti-G-CSF antibody was topically administered to the gingiva surrounding the maxillary first molar (the anti-G-CSF group), and tissues including gingival mucosa and jawbone were collected and evaluated histopathologically.
TRAP staining showed no significant TRAP-positive osteoclasts in the control group or the anti-G-CSF group, and HE staining showed alveolar bone resorption in the first molar. Although there was no obvious bone exposure, the anti-G-CSF group showed a decrease in empty lacunae compared to the control group.

Free Research Field

口腔外科

Academic Significance and Societal Importance of the Research Achievements

骨粗鬆症や骨転移を有する悪性腫瘍の患者の治療に広く用いられている骨吸収抑制薬の重
大な副作用の一つに骨吸収抑制薬関連顎骨壊死があり、患者数は増加傾向にある。炎症の制御が困難になると、腫脹、疼痛、外歯瘻などで患者の口腔に関するQOLは著しく低下するため、軟組織を含めた炎症の局所コントロールは重要である。骨吸収抑制薬関連顎骨壊死という軟組織を含めた炎症性疾患は、活動亢進した好中球による好中球介在性疾患とみなされるのではないかという問いを明らかにし、活性化した好中球を制御できれば、患者の口腔に関するQOL維持に繋がると考えられる。